Eli Lilly and Company (LLY)
US FDA says all doses of Lilly's weight-loss and diabetes drug now available
All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday.
Why Eli Lilly Stock Trounced the Market on Thursday
The pharmaceutical giant's CEO had some very good news to report about a hot product. The medication should come off the FDA's shortage list in the immediate future, according to him.
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
Easily one of the biggest trends right now in the field of medicine is the weight loss drug surge. Without attempting to sound cynical, the reality is that the sector enjoys a massive total addressable market.
Lilly CEO says weight-loss drug shortage to end 'very soon', Bloomberg News reports
U.S. drugmaker Eli Lilly expects its blockbuster weight-loss drug to officially come out of shortage in the United States in coming days, Bloomberg News reported on Thursday, citing an interview with the company's chief executive officer, David Ricks.
Eli Lilly Weight-Loss Drug Could Also Treat Heart Failure, Study Shows
The active ingredient in Eli Lilly's (LLY) flagship weight-loss drug has a new potential indication: heart failure treatment.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly Finds Another Condition for Zepbound to Treat. The Stock Is Up.
The drug appears to have hit a home run treating a common form of heart failure.
What You Need to Know Ahead of Eli Lilly Earnings
Eli Lilly (LLY) reports earnings before markets open on August 8, with analysts projecting revenue and profits to be boosted by the popularity of the weight-loss drugs Mounjaro and Zepbound.
Lilly says weight loss drug cut heart failure risk by 38% in trial
Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.
Japan health ministry panel backs Eli Lilly dementia drug donanemab
A Japanese health ministry panel on Thursday recommended approval for Eli Lilly's dementia treatment donanemab.
Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Sagimet Biosciences is progressing with Denifanstat research targeting MASH, acne, and cancer with promising Phase 2b trial results. Denifanstat is progressing toward Phase 3 trials, with positive results reinforcing its potential, especially for hepatic-impaired patients. Eli Lilly's Tirzepatide presents strong competition for Denifanstat in MASH treatment, showing higher efficacy in recent trials.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
